prikaz prve stranice dokumenta miRNA in prostate cancer: challenges toward translation
  Preuzmi
PDF 1.64 MB
Znanstveni rad - Izvorni znanstveni rad
miRNA in prostate cancer: challenges toward translation
Epigenomics, 12 (2020), 6; 543-558. https://doi.org/10.2217/epi-2019-0275
Abramović, Irena; Ulamec, Monika; Ana, Katušić Bojanac; Bulić-Jakuš, Floriana; Ježek, Davor; Sinčić, Nino

Citirajte ovaj rad

Abramović, I., Ulamec, M., Ana, K. B., Bulić Jakuš, F., Ježek, D. i Sinčić, N. (2020). miRNA in prostate cancer: challenges toward translation. Epigenomics, 12. (6), 543-558. doi: 10.2217/epi-2019-0275

Abramović, Irena, et al. "miRNA in prostate cancer: challenges toward translation." Epigenomics, vol. 12, br. 6, 2020, str. 543-558. https://doi.org/10.2217/epi-2019-0275

Abramović, Irena, Monika Ulamec, Katušić Bojanac Ana, Floriana Bulić Jakuš, Davor Ježek i Nino Sinčić. "miRNA in prostate cancer: challenges toward translation." Epigenomics 12, br. 6 (2020): 543-558. https://doi.org/10.2217/epi-2019-0275

Abramović, I., et al. (2020) 'miRNA in prostate cancer: challenges toward translation', Epigenomics, 12(6), str. 543-558. doi: 10.2217/epi-2019-0275

Abramović I, Ulamec M, Ana KB, Bulić Jakuš F, Ježek D, Sinčić N. miRNA in prostate cancer: challenges toward translation. Epigenomics [Internet]. 03.2020. [pristupljeno 20.12.2024.];12(6):543-558. doi: 10.2217/epi-2019-0275

I. Abramović, M. Ulamec, K. B. Ana, F. Bulić Jakuš, D. Ježek i N. Sinčić, "miRNA in prostate cancer: challenges toward translation", Epigenomics, vol. 12, br. 6, str. 543-558, Ožujak 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:146208. [Citirano: 20.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:146208
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)miRNA in prostate cancer: challenges toward translation
AutorIrena Abramović
AutorMonika Ulamec
AutorKatušić Bojanac Ana
AutorFloriana Bulić-Jakuš
AutorDavor Ježek
AutorNino Sinčić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA HISTOLOGIJU I EMBRIOLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MEDICINSKU BIOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Citologija, histologija i embriologija
Sažetak (engleski)
Prostate cancer (PCa) represents the most commonly diagnosed neoplasm among men. miRNAs, as biomarkers, could further improve reliability in distinguishing malignant versus nonmalignant, and aggressive versus nonaggressive PCa. However, conflicting data was reported for certain miRNAs, and there was a lack of consistency and reproducibility, which has been attributed to diverse (pre)analytical factors. In order to address current challenges in miRNA clinical research on PCa, a PubMed-based literature search was conducted with the last update in May 2019. After identifying critical variations in designs and protocols that undermined clear-cut evidence acquisition, and reliable translation into clinical practice, we propose guidelines for most critical steps that should be considered in future research of miRNA as biomarkers, especially in PCa.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEpigenomics
Brojčani podacivol. 12, br. 6, str. 543-558
p-ISSN1750-1911
e-ISSN1750-192X
DOIhttps://doi.org/10.2217/epi-2019-0275
URN:NBNurn:nbn:hr:105:146208
Datum objave publikacije2020-03
URL dokumentahttps://www.futuremedicine.com/doi/10.2217/epi-2019-0275
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2021-04-16 08:49:37